共 50 条
To switch (statins) or not to switch? That is the question
被引:7
作者:
Athyros, Vasilios G.
[3
]
Tziomalos, Konstantinos
[2
]
Karagiannis, Asterios
[3
]
Mikhailidis, Dimitri P.
[1
]
机构:
[1] UCL, Univ Coll London Med Sch, Dept Clin Biochem, London NW3 2QG, England
[2] Aristotle Univ Thessaloniki, Sch Med, AHEPA Univ Hosp, Propedeut Dept Internal Med 1, GR-54006 Thessaloniki, Greece
[3] Aristotle Univ Thessaloniki, Sch Med, Hippokrat Hosp, Propedeut Dept Internal Med 2, GR-54006 Thessaloniki, Greece
关键词:
cardiovascular disease;
cholesterol;
cost;
generic;
goals;
statin;
switching;
CORONARY-ARTERY-DISEASE;
LIPID-LOWERING THERAPY;
HEART-DISEASE;
SIMVASTATIN;
ATORVASTATIN;
OUTCOMES;
METAANALYSIS;
TRIALS;
ROSUVASTATIN;
REVERSAL;
D O I:
10.1517/14656566.2010.522991
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Cost is an important consideration when deciding which drugs to prescribe. The problem is becoming more evident because effective, well-tolerated and evidence-based generic drugs are now widely available. More specifically, switching to a cheaper statin formulation might result in less effective treatment in terms of event reduction or achievement of lipid goal. Better patient adherence to treatment is also not always achieved by switching to generics. This editorial considers this debate.
引用
收藏
页码:2943 / 2946
页数:4
相关论文
共 50 条